Biotechnology is advancing at a pace that few industries have experienced before. New therapies, AI-driven diagnostics, and data-intensive research are reshaping healthcare, often faster than the structures meant to safeguard them can adapt. The challenge is whether organizations can build systems that absorb speed without sacrificing trust. For Chris Mashburn, Chief Operating and AI Officer at Jorie Healthcare Partners, this is where many healthcare and biotech efforts falter because they treat compliance as a checkpoint. “As I started going through the compliance matrix, I realized this is the same relevance that I had while working in security,” says Mashburn. “It was kind of an aha moment.”
A retired Captain with the Texas Highway Patrol, Mashburn spent years immersed in security and crisis response before moving into healthcare and biotechnology. Over the course of his career, he’s come to see security as a way to engineer resilience into complex, fast-moving systems. “If you don’t think about it along the way, when you get to that endpoint, it’s really not the finished product,” he says.
At Jorie Ai, an Ai and Automation company supporting physician practices, ambulatory surgery centers, hospital systems and healthcare operations globally, Mashburn leads the integration of AI, compliance, and operational execution. The work has taught him that bridging biotech and security is less about control and more about design. When compliance, documentation, and security thinking are embedded early, they become accelerators of scale rather than brakes on innovation, translating regulatory requirements into systems that can function reliably in day-to-day healthcare operations.
Tension Between Innovation and Oversight
There’s an inherent tension between the way scientists and physicians work and the mindset required for compliance. The problem is not resistance to security itself, but the perception that it distracts from discovery. “You have physicians and scientists and engineers wanting to focus on the solution and whatever it takes to get to that endpoint,” he says. “To tell them that during that journey you’ve got to be constantly thinking about compliance, there can in fact be tension.”
Over time, he has focused on reframing compliance as a tool rather than an obstacle. The early transition was, in his words, rocky. But credibility, built through repeated execution, changed the dynamic. Security became part of the workflow.
Building Biosecurity That Works on the Ground
Effective biosecurity requires systems and capabilities that operate in real environments. Mashburn consistently returns to three core investments he sees as non-negotiable for leaders trying to bridge biotech and security. The first is technology, particularly AI. Provided it is designed with compliance at its core, automation can help to bridge the gap between manual processes and increasingly complex regulatory and security demands. At Jorie Ai, this is exactly what we deliver time after time.
The second is people. “Find the individuals who have experienced both security compliance and biotechnology or healthcare compliance,” he says. That crossover expertise allows organizations to anticipate conflicts before they surface and align operational efficiency with regulatory expectations.
The third is discipline in documentation. Standard operating procedures are often underestimated, yet Mashburn treats them as foundational. Documented processes make compliance repeatable and scalable, reducing reliance on individual judgment in high-risk environments. “It becomes a standard part of your process,” he says, rather than a reactive exercise.
AI, Trust, and the Next Phase of Risk
As algorithms begin to design molecules and predict biological outcomes faster than human teams can review them, traditional security models strain to keep pace. What concerns him most is adoption. “There’s still a skepticism from some physicians and scientists that they can’t quite depend on it yet,” he says. That trust gap is what keeps him focused. Mashburn believes AI, when properly governed, can strengthen compliance and security while supporting professionals at the front lines of care and research. His forthcoming book on AI myths reflects that conviction, aiming to demystify the technology for those shaping the future of healthcare.
The stakes are high. If science accelerates without security evolving alongside it, risk multiplies. If security constrains innovation, scientific progress can stall. Mashburn’s work sits in the narrow but critical space between those extremes, proving that biotech and security are complementary forces.
